about
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialRaltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionHIV care in Yangon, Myanmar; successes, challenges and implications for policy.Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapyMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).Recent trends in early stage response to combination antiretroviral therapy in Australia.The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaRates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region.HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.CD4(+) T Follicular Helper and IgA(+) B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected IndividualsTreatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocolAgeing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experienceIndinavir: the forgotten HIV-protease inhibitor. Does it still have a role?Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research.Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.Improvements in antiretroviral therapy outcomes over calendar time.Antiretroviral roll-out: the problem of second-line therapy.Current and future management of treatment failure in low- and middle-income countries.Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Optimisation of HIV care and service delivery: doing more with less.Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.Which HIV patients should be screened for osteoporosis: an international perspective.Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard firThe clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.Sexual transmission of HIV and the law: an Australian medical consensus statement.Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.Tenofovir alafenamide: safer, but questions remain.Novel antiretroviral agents and universal access to HIV care.The LATTE study: a provocative brew.
P50
Q28540037-8D391302-FB42-4A3E-A634-627919AD0567Q28543732-FEDB42DF-C028-4633-B0DC-E2674A65F315Q30378383-1610C3E8-76CB-4593-AAD7-017745EA5603Q31106702-EDC767E5-EEA4-4D26-930E-1E940A103F51Q33603586-D49E6DE5-B960-46E4-9106-D157A869C131Q33824851-3F7C04CC-D10D-4790-BC0A-4926DFFB1338Q34289433-A703788B-9974-4D95-95F9-F4C423ABCA81Q34606231-E2920730-29CB-464A-87BA-D2FF6629332BQ34804309-B60A35EB-9C10-487E-9F91-E07640B3D02FQ35035055-DC26018A-8AB8-4528-AE47-AB445278DB65Q35149475-39B16017-FC3B-455F-87B0-C31EB22B8118Q35947529-0B112D6B-E67B-408D-8322-6D82E92517E8Q36185114-C4A7C85F-5FAA-46CD-B786-C5F37E7A4B73Q36243066-4CAA54E2-ABF8-4B1A-802B-DEFEBB9CC47BQ36565914-B5D8FFB3-7FAE-4E51-9764-2C872CEAA355Q36808038-9AB4DECD-0A0F-46DC-AF03-BBD8C3202F8FQ36874618-0244CC12-5ECC-4908-84A4-721A16A5818DQ37086478-5DCBB4FA-ABE1-453F-8FFA-04D5A450E3A0Q37272765-39F76834-C1CC-4F72-BA7A-54B02ABC50F9Q37521685-6F8D5970-4093-4891-A8E5-AD125C76FBBAQ37555574-4A0F27B2-E041-4FE4-B3BE-70186E869212Q37666465-AC53C2F3-6E09-451A-BD44-E22CCBB59DB6Q37695051-4575394E-5F58-4CC4-89BA-91763B2A1FD9Q37765753-A7846146-6546-4F0F-AE5F-7A466958347FQ37823558-9B8F2B97-1783-47AF-AC81-26DF6ECE723BQ38029217-69CF22EF-9FF8-472F-92C6-A6C6E02D3FF6Q38170576-C65118C4-7235-4C5A-8F0C-6ABE2308178EQ38484316-CBF43933-9A7D-493F-AE7A-BC9D6D04F0FAQ38741240-A5982852-EC25-48DC-86A0-9B5F596027EDQ38836703-A8950EA4-BD5B-42D6-A4F3-F87B0A861BDCQ39158094-03985904-35BE-4866-910D-3A82EAED106BQ39214073-61B53C71-C8AF-4955-8AA5-1BB1D0175AFEQ40095857-BA98350C-C585-4ED7-99CF-ABAC03A08BE1Q40225806-06A49ADD-760C-45CB-AB22-9162FF3DB27EQ40294920-CF281296-F140-42DB-B774-78338AAF9AE6Q40465671-33E95AE9-5849-41B9-9975-BA31B3B4A868Q40480144-18464508-682D-4840-9BAF-1FBB3BD73C15Q40731833-A05C3040-7F6E-4026-B680-6E70466BD6E6Q40834723-30EBCCEF-350E-4F7D-8A86-74B66929C324Q41095313-B50C6879-C852-4902-AC02-1C24C23B40CC
P50
description
researcher ORCID ID = 0000-0002-6848-3307
@en
wetenschapper
@nl
name
Mark A Boyd
@ast
Mark A Boyd
@en
Mark A Boyd
@es
Mark A Boyd
@nl
type
label
Mark A Boyd
@ast
Mark A Boyd
@en
Mark A Boyd
@es
Mark A Boyd
@nl
prefLabel
Mark A Boyd
@ast
Mark A Boyd
@en
Mark A Boyd
@es
Mark A Boyd
@nl
P108
P108
P21
P31
P496
0000-0002-6848-3307